Top 10 Animal Health Companies

Why Animal Health Market Is Expanding?

The Global Animal Health Market is on a robust and sustained growth trajectory, rising from USD 74.17 billion in 2025 to a projected USD 162.08 billion by 2035, at a CAGR of 8.13% over the 2025–2035 forecast period. Market Research Future (MRFR) identifies two co-equal primary demand engines: the accelerating global demand for animal protein and the rapid adoption of preventive healthcare technologies, which have expanded vaccination and diagnostic coverage across both livestock and companion animal populations. The convergence of rising pet ownership, intensifying livestock production, and digital health infrastructure investment provides self-reinforcing structural tailwinds that sustain above-baseline growth well through the 2035 forecast horizon.

The American Pet Products Association (APPA) estimates that about 67% of families in the United States own at least one pet, highlighting the size of the long-term demand for companion animal healthcare. The World Organisation for Animal Health (WOAH) also states that worldwide livestock production must grow by 70% by 2050 to fulfill predicted protein demand, which will directly raise the need for veterinary medications, vaccines and feed additives across all geographies.

The largest segment in terms of products is Animal Health Vaccines, fueled by rising awareness of vaccination and regulatory demands for disease control in livestock. Animal Health Feed Additives is the fastest expanding market driven by increase in agricultural productivity demands and increased health standards. By animal type, the most dominant and largest share are held by food producing animals because to the long-term demand for cattle, poultry, and swine health management. In terms of distribution channel, the Veterinary Hospitals & Clinics segment dominates the market, while E-Commerce is the fastest growing channel and is anticipated to achieve substantial scale by 2035.

Why These Companies Are Leading the Market?

MRFR identifies four structural elements that define category leadership in the Animal Health Market: integrated product portfolio breadth across pharmaceuticals, vaccines, diagnostics, and feed additives; geographic scale and multi-market distribution density; technology investment in biologics, gene therapy, and digital health platforms; and a disciplined M&A strategy to acquire complementary assets that broaden therapeutic reach and species coverage. Zoetis is the industry leader for the breadth of its integrated portfolio, with revenue of USD 9.26 billion in 2024, covering more than 300 product lines spanning over 100 countries.

Boehringer Ingelheim is globally active, with a presence in more than 150 markets and an animal health business of EUR 4.9 billion. Merck Animal Health’s competitive path is defined by investment in technology, including the acquisition of a gene-editing biotechnology company in 2025 to incorporate advanced genetic solutions. Consolidation driven by M&A has informed the competitive positioning of Elanco Animal Health, which completed the acquisition of Kindred Biosciences in 2021 to enhance biologics pipeline capabilities.

Top 10 Global Animal Health Companies — MRFR Rankings (2026)

*Rankings reflect MRFR's qualitative assessment of scale and market influence in the animal health sector. Revenue figures are drawn from SEC filings and official investor disclosures where the company is publicly traded; figures for private companies are third-party estimates and are clearly marked as such, since none of the private companies profiled disclose audited segment revenue publicly.

Detailed Company Profiles

1. Zoetis | NYSE: ZTS | Parsippany, New Jersey, USA

Zoetis is the world’s largest standalone animal health company, with the biggest proportion of revenue of the global animal health market, with USD 9.26 billion in FY2024 revenue (SEC 10-K). The company operates in over 100 countries and offers nearly 300 product lines for the prediction, prevention, detection and treatment of disease across eight key species.

The structural differentiator for Zoetis is its intentional portfolio diversity – 68% companion animal and 32% livestock – which offers a buffer from the commodity price cycles in agriculture while still capturing premium pricing in the pet care market. Zoetis’ 2024 FDA approval of Librela (a monoclonal antibody for canine osteoarthritis) and USD 200 million investment in a new R&D center in Singapore are part of a strategic pivot towards biologics and precision animal health, positioning the company to ride the next wave of therapeutic innovation that extends beyond traditional small-molecule pharmaceuticals.

2. Merck Animal Health (MSD) | Division of Merck & Co. (NYSE: MRK) | Rahway, New Jersey, USA

Merck Animal Health is the animal health subsidiary of Merck & Co. with USD 5.9 billion sales in FY2024 (SEC 10-K) which represent 9% of the overall revenues of Merck group. Merck’s differentiator is its dual-engine growth model: BRAVECTO (companion animal parasiticide) delivered $1.1 billion in sales in 2024 and its July 2024 acquisition of Elanco’s aqua business and the September 2025 gene-editing biotech acquisition demonstrate a strategic commitment to both portfolio breadth and technology frontier expansion. The company’s geographic distribution (46% Americas, 30% Europe, 24% Asia/Africa) provides natural hedging against regional demand shocks.

3. Boehringer Ingelheim | Family-Owned | Ingelheim am Rhein, Germany

Boehringer Ingelheim is the world’s largest family-owned pharmaceutical firm. In 2025, the Animal Health segment generated revenues of EUR 4.9 billion and is the second-largest supplier of veterinary vaccines and treatments in the world. In January 2017, the company dramatically changed its strategic position by exchanging its consumer healthcare business for Sanofi’s animal health division (Merial), creating a EUR 3.9 billion animal health platform overnight.

Ongoing progress on the Merial integration thesis is evidenced by the opening of a state-of-the-art vaccine production plant in Lyon, France in 2024 and the EUR 1.4 billion NexGard revenue milestone in 2025 (+8.5%). Boehringer Ingelheim is a family-owned company and doesn’t feel the same pressure of quarterly results that publicly traded companies do. This allows it to make multi-year bets on R&D that publicly traded competitors could find difficult to explain.

4. Elanco Animal Health | NYSE: ELAN | Greenfield, Indiana, USA

Elanco Animal Health is a global leader in animal health with FY2025 sales of USD4.72 billion (SEC 10-K) and operates in 90+ countries. Portfolio re-composition has been a hallmark of the company’s strategic trajectory, with the acquisition of Kindred Biosciences in August 2021 strengthening biologics capabilities and the sale of the aqua business to Merck Animal Health in July 2024 sharpening the focus on core livestock and companion animal therapeutics.

Elanco’s 6% YoY revenue increase and 55% gross margin is indicative of operational execution in a competitive pricing environment. The company’s portfolio is well spread amongst medications, vaccines and feed additives, with a strong presence in the cattle and poultry health segments.

5. Virbac | Euronext Paris: VIRP | Carros, France

Virbac is a multinational veterinary pharmaceutical firm headquarted in France. Reported FY2025 sales was EUR 1.47 billion with 7.9% organic growth at constant exchange rates (firm IR). The company has differentiated itself strategically through a companion animal-centric portfolio, representing 73.7% of group revenue and regional diversification throughout the US (+14.7% CERS growth), Europe, Latin America and Asia-Pacific.

Virbac’s drive for innovation in high-margin companion animal therapies is illustrated by its 2025 acquisition of Thyronorm (feline hyperthyroidism therapy) and the launch of Vikaly (the world’s first medicated petfood). Virbac controls its value chain from end to finish with 21 R&D centers and 32 production units.

6. Ceva Santé Animale | Private (PSP Investments, Mérieux families) | Libourne, France

Ceva Santé Animale is the world’s 5th largest animal health company and the largest privately held veterinary pharmaceutical company with EUR 1.77 billion in FY2024 revenue – a 14x increase since its foundation in 1999. The company is strategically focused on preventative medicine and immunization, with 7,000+ workers and 32 production facilities in 47 countries.

Ceva was the first veterinary business to create and commercialize a nucleotide vaccine, and has invested in gene therapy for companion animals, showing leadership in next generation biologics technology. The March 2025 shareholding restructure ensures long term capital stability without the strain of public market quarterly earnings with PSP Investments and Mérieux families taking larger holdings.

7. Dechra Pharmaceuticals | Private (EQT, Abu Dhabi Investment Authority) | Northwich, UK

Dechra Pharmaceuticals is a global specialty veterinary pharmaceutical business. Dechra Pharmaceuticals has revenues of GBP 369.1 million in FY2024 (Section 172 Statement) and is present in 89 countries. Strategic bias towards companion animal goods (73.7% of revenue) and specialized treatments give the company an attractive distinctive position in the mid-market between global giants and generic manufacturers.

The April 2024 acquisition of STEM Animal Health (dental biofilm treatments) and the September 2024 acquisition of Invetx (biopharmaceuticals, up to USD 520M total consideration) reflect a dual-track M&A strategy: consolidating specialty therapeutic areas while strengthening biologics capabilities. Dechra spends 8.3% of revenue on R&D, well above industry averages.

8. Heska Corporation | Subsidiary of Mars, Incorporated | Loveland, Colorado, USA

Heska Corporation is a major developer of advanced veterinary diagnostic and specialty solutions, bought by Mars, Incorporated in June 2023 for roughly USD 1.3 billion (based on USD 120.00 per share). The Company offers a subscription-based diagnostics business spanning the US, Europe, Australia, Brazil and Asia, combining point-of-care testing tools with recurring consumable income streams.

Heska provides a complementary diagnostic technology platform for Mars’s current network of veterinary services (AniCura, Antech, BANFIELD, BLUEPEARL, Linnaeus, VCA) and hence has strategic significance to Mars. Heska is a private subsidiary and no longer reports standalone financials, but its integration into Mars’s USD 45 billion revenue ecosystem provides access to funding and distribution channels inaccessible to standalone diagnostics companies.

9. Phibro Animal Health | NASDAQ: PAHC | Teaneck, New Jersey, USA

Phibro Animal Health is a diversified animal health and mineral nutrition firm. The company provided net sales projection of USD 1.45–1.50 billion for FY2026 (SEC 10-Q, Q2 2025). The company’s strategic inflection point was the October 2024 acquisition of the medicated feed additive (MFA) portfolio from Zoetis for USD 350 million that delivered 21% Q2 revenue growth and 41% adjusted EBITDA growth.

Phibro has three segments: Animal Health (MFAs, nutritional specialty, vaccinations), Mineral Nutrition & Performance Products with specific strength in poultry and swine health. The company’s Animal Health division grew 26% in Q2 2025, with robust demand in Latin America and Southeast Asia, and successful integration of acquired assets.

10. Bayer Animal Health | Division of Bayer AG (ETR: BAYN) | Leverkusen, Germany

Bayer Animal Health is a business unit of Bayer AG, a German pharmaceutical and chemical group with sales of EUR 46.6 billion. The animal health division makes a significant but secret contribution to the group's revenue and is strategically focused on parasiticides, dermatological and livestock pharmaceuticals in more than 100 countries.

The appointment of Dr. Anna Müller as Head of Animal Health Division in January 2025 is a hint of a renewed managerial focus on the segment, which has seen years of relative underinvestment compared to the pharmaceutical and crop science divisions. Bayer’s animal health portfolio benefits from the worldwide manufacturing infrastructure and regulatory knowledge of the parent firm, however competition for capital allocation with higher profit human pharma businesses is a perennial constraint.

M&A Activity Tracker (2021–2025)

Key Trend

MRFR analysis identifies biologics and gene therapy integration as the dominant M&A theme in the animal health market. Zoetis's USD 200 million Singapore R&D center and Merck's gene-editing acquisition demonstrate that competitive differentiation is shifting from traditional small-molecule pharmaceuticals toward monoclonal antibodies, nucleotide vaccines, and genetic disease resistance. A parallel theme is vertical integration of diagnostics into veterinary service networks, illustrated by Mars's acquisition of Heska to instrument its 1,000+ hospital network, creating captive demand for consumables and test panels that standalone diagnostics competitors cannot replicate.

R&D Investment & Innovation Signals

• Zoetis is continuing to grow its biologics portfolio with FDA approval of Librela (canine osteoarthritis monoclonal antibody) in Q2 2024 and the USD 200 million Singapore R&D center investment in Q2 2025, indicating a strategic move from traditional pharmaceuticals to precision animal health therapeutics that command premium pricing and higher margins.
• Merck Animal Health's September 2025 acquisition of a gene-editing biotechnology firm and the July 2024 Elanco aqua business acquisition demonstrate a dual-track innovation strategy: frontier genetic technologies for long-term competitive moats and species diversification to capture protein demand shifts toward aquaculture.
• Confirmation of the 2017 Merial integration thesis with Boehringer Ingelheim’s 2024 opening of its Lyon vaccine facility and EUR 1.4 billion NexGard revenue milestone in 2025 (+8.5%), with the family-owned capital structure enabling multi-year R&D bets on vaccine development that could be tough for publicly traded competitors to justify to shareholders.
• Virbac’s 7.9% organic growth in 2025, driven by 10.9% growth in its companion animal segment and the launch of Vikaly (world’s first medicated petfood), shows that mid-tier players can achieve above-market growth via therapeutic innovation in high-margin pet care segments, rather than competing on price in commoditized livestock markets.
• Ceva Santé Animale's status as the first veterinary company to develop a nucleotide vaccine and its investment in gene therapy for companion animals positions it as a technology leader among private competitors, with the EUR 1.77 billion revenue scale providing sufficient resources for global R&D without public market quarterly earnings pressure.
• Dechra Pharmaceuticals invests 8.3% of revenue in R&D, which is significantly above industry averages, and a dual-track M&A strategy (STEM Animal Health for dental biofilm, Invetx for biopharmaceuticals up to USD 520M) that creates both niche therapeutic depth and next-generation biologics capabilities in the mid-market segment.
• Phibro Animal Health's October 2024 acquisition of Zoetis's USD 350 million MFA portfolio transformed its growth trajectory from mid-single-digit to double-digit revenue growth, though the company faces regulatory exposure to antibiotic-use restrictions in livestock feed that could constrain the acquired portfolio's long-term value if regulatory frameworks tighten within the forecast period.
• Elanco Animal Health's Kindred Biosciences acquisition in August 2021 (USD ~444M) represents a necessary strategic hedge against generic competition in traditional pharmaceuticals, though execution risk remains in integrating acquired R&D platforms and achieving projected biologics revenue contributions within the 2025–2035 forecast horizon.